title: One step forward or one step back with tamoxifen?
authors.affiliation: British Columbia Cancer Agency, Vancouver, Canada.
authors.forename: K
authors.initials: K
authors.lastname: Gelmon
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000473:pathology; D004965:Estrogen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D018570:Risk Assessment; D012307:Risk Factors; D015996:Survival Rate; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000139:chemically induced / Q000473:pathology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013629:Tamoxifen